Akcea Therapeutics

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. .

Akcea: Uninteresting Slow Growth Stock With Long-Term Potential

BOSTON, June 9, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Kia Motesharei, Ph.D., has joined the company as Senior Vice President of Business Development & Corporate Strategy. In this role...

Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy

BOSTON, June 8, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that AIFA, or The Italian Medicines Agency, has granted approval for the reimbursement of TEGSEDI® (inotersen) for the treatment of...

Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy

BOSTON, June 1, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the Portuguese Medicine Regulatory Authority (INFARMED) has granted approval for reimbursement of TEGSEDI® (inotersen) for the treatment...

Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Portugal for treatment of hereditary transthyretin amyloidosis with polyneuropathy

Results from the ongoing, open-label extension (OLE) study of the pivotal NEURO-TTR trial published in the European Journal of Neurology show that patients treated with TEGSEDI® (inotersen) experienced sustained improvements in measures of neuropathic progression at 39 months of therapy, and clinically relevant improvements in measures of quality of life compared to the natural history of the disease

Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by Hereditary Transthyretin Amyloidosis Demonstrating Sustained Improvements and Even Greater Stabilization in Patients Starting Earlier Tre

BOSTON, May 18, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined the company as executive vice president and chief financial officer. In this role, Mr. Price will...

Akcea Announces Appointment of New Chief Financial Officer

BOSTON, May 14, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced The Ministry of Health of Spain (MSCBS) has granted approval for the reimbursement of TEGSEDI® (inotersen) in the treatment of stage 1...

Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy

Akcea (AKCA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Akcea (AKCA) Stock Might be a Great Pick

Akcea Therapeutics, Inc. (AKCA) CEO Damien McDevitt on Q1 2020 Results - Earnings Call Transcript

Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of 6.67% and -70.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Akcea Therapeutics (AKCA) Reports Q1 Loss, Misses Revenue Estimates

Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Akcea Therapeutics (AKCA) Q1 Earnings Expected to Decline

BOSTON, March  24, 2020  (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that its board of directors has appointed Damien McDevitt, Ph.D. as Chief Executive Officer, effective immediately.  Dr. McDevitt has served as interim CEO of Akcea since September 2019 and will continue to serve as a member of the Akcea board of directors.

Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO

BOSTON, March  11, 2020  (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Lisa Johnson-Pratt, M.D., has joined the company as senior vice president of new product strategy. In this role, Dr. Johnson-Pratt will drive Akcea’s corporate strategy and provide strategic support for the development and commercialization of new pipeline products. She will report to Damien McDevitt, Ph.D., interim chief executive officer at Akcea. The company also announced the appointment of Joshua Patterson as general counsel. Mr. Patterson previously served as vice president, legal and corporate secretary at Akcea.

Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company’s leadership team

Akcea Therapeutics, Inc. (AKCA) CEO Damien McDevitt on Q4 2019 Results - Earnings Call Transcript

BOSTON, Feb.  13, 2020  (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the appointment of Amber Salzman, Ph.D., to the Company’s Board of Directors, expanding the board to 11 members. Dr. Salzman has more than 30 years of experience in the pharmaceutical industry including serving as chief executive officer (CEO) of several companies, both publicly traded and private.

Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman

Ionis Pharma

Both primary as well as multiple secondary endpoints were met in the trial.

Akcea and Ionis Confirm Positive Trial Results for Hypertriglyceridemia Treatment

Favorable safety and tolerability were observed

Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx

The drug will advance to studies in familial chylomicronemia syndrome and other diseases that result in high triglyceride levels.

Akcea and Ionis' Triglyceride-Lowering Drug Works in Mid-Stage Clinical Trial

Shares of Ionis Pharmaceuticals and Akcea Therapeutics popped Wednesday after the biotech companies said their high triglycerides treatment succeeded in a midstage study.
The post Will These Biotechs Rival A Top-Notch Stock In High Triglycerides?

Will These Biotechs Rival A Top-Notch Stock In High Triglycerides?

Akcea Therapeutics Inc. (NASDAQ: AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ: IONS) each made handy gains on Wednesday after they reported midstage results for their cardiovascular disease study.

Why This Cardiovascular Disease Study Could Be Huge

BOSTON and CARLSBAD, Calif., Jan.  10, 2020  (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the initiation of the CARDIO-TTRansform Phase 3 cardiovascular outcomes study for AKCEA-TTR-LRx in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR cardiomyopathy). 

Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy

Patients treated with AKCEA-APO(a)-LRx received pre-specified endpoints for Lp(a) levels with favorable safety and tolerability profile

New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease

Data from Phase 2 clinical trial of AKCEA-APOCIII-LRx anticipated in early 2020 Data from Phase 2 clinical trial of AKCEA-APOCIII-LRx anticipated in early 2020

Akcea Retains Rights to AKCEA-APOCIII-LRx

Lynne Parshall appointed chair and Barbara Yanni joins as new member of the Akcea board Lynne Parshall appointed chair and Barbara Yanni joins as new member of the Akcea board

Akcea Therapeutics Announces New Appointments to its Board of Directors

AMAG Pharmaceuticals

Axsome Therapeutics

Cronos Group

Eidos Therapeutics Inc

Heron Therapeutics

Ligand Pharmaceuticals

Paratek Pharma

PolarityTE Inc

Viking Therapeutics

Intrexon

ZIOPHARM Oncology

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

News for Akcea Therapeutics Stock (AKCA)